Capricor Therapeutics CAPR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $287.85M+2,450% | $11.29M-23.2% | $14.69M+53.0% | $9.6M-72.5% | ||
| $30.28M-78.4% | $140.23M+466% | $24.79M-22.1% | $31.82M— | ||
| $322.94M+97.7% | $163.39M+221% | $50.86M+18.6% | $42.89M+17.7% | ||
| $18.31M+229% | $5.56M0.0% | $5.56M+21.2% | $4.59M+156% | ||
| $355.95M+109% | $170.48M+190% | $58.73M+17.2% | $50.09M+21.2% | ||
| $1.65M-49.6% | $3.28M-47.5% | $6.25M+29.3% | $4.83M+55.1% | ||
| $12M0.0% | $12M-50.6% | $24.27M+35.0% | $17.98M— | ||
| $35.84M+70.4% | $21.03M-32.8% | $31.27M+32.6% | $23.59M+471% | ||
| $14.32M+259% | $3.99M-17.9% | $4.86M-67.0% | $14.72M+153% | ||
| $50.16M+100% | $25.02M-30.8% | $36.13M-5.7% | $38.31M+285% | ||
| $57.37K+25.9% | $45.58K+46.3% | $31.15K+23.4% | $25.24K+4.4% | ||
| -$304.88M-52.6% | -$199.83M-25.4% | -$159.37M-16.3% | -$137.08M-26.9% | ||
| $305.79M+110% | $145.46M+544% | $22.6M+91.8% | $11.79M-62.4% | ||
| $355.95M+109% | $170.48M+190% | $58.73M+17.2% | $50.09M+21.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Capricor Therapeutics cover its short-term obligations?
- Its current ratio is 8.42 — current assets exceed current liabilities.
- Where does Capricor Therapeutics's balance sheet data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.